Table 1. Meta-analysis results of subgroups.
| subgroup | number of studies | number of patients | ES[95% Conf. Interval] | Test of Heterogeneity | Significance test(s) publication bias | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | I-squared | Z | P | begg's P | egger's P | ||||
| ovarian cancer | 4 | 418 | 1.93 | 1.19 to 3.15 | 45.30% | 2.65 | 0.008 | 0.734 | 0.679 | |
| neuroblastoma | 2 | 112 | 4.03 | 1.91 to 8.50 | 0.00% | 3.65 | 0 | - | - | |
| ENT tumor | 4 | 759 | 2.39 | 1.70 to 3.36 | 0.00% | 5.00 | 0 | 0.174 | 0.017 | |
| hematological malignancy | 3 | 312 | 2.45 | 1.69 to 3.56 | 0.00% | 4.72 | 0 | 0.296 | 0.213 | |
| breast cancer | 3 | 1678 | 1.4 | 0.85 to 2.30 | 85.00% | 1.32 | 0.186 | 1 | 0.584 | |
| digestive system cancers | 5 | 865 | 1.09 | 0.49 to2.41 | 86.50% | 0.21 | 0.836 | 1 | 0.777 | |
HR: hazard ratio. 95% CI: 95% confidence interval.